|
1) Segawa H, Onitsuka A, Kuwahata M, et al. Type IIc sodium-dependent phosphate transporter regulates calcium metabolism. J Am Soc Nephrol. 2009; 20: 104-13
|
|
|
|
2) Segawa H, Onitsuka A, Furutani J, et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol. 2009; 297: F671-8
|
|
|
|
|
|
3) Popovtzer MM, Massry SG, Makoff DL, et al. Renal handling of phosphate in patients with chronic renal failure. The role of variations in serum phosphorus and parathyroid activity. Isr J Med Sci. 1969; 5: 1018-23
|
|
|
|
|
|
4) Cai Q, Hodgson SF, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994; 330: 1645-9
|
|
|
|
|
|
5) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26: 345-8
|
|
|
|
|
|
6) Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001; 98: 6500-5
|
|
|
|
|
|
7) Yu X, Ibrahimi OA, Goetz R, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology. 2005; 146: 4647-56
|
|
|
|
|
|
8) Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444: 770-4
|
|
|
|
|
|
9) Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19: 429-35
|
|
|
|
|
|
10) Razzaque MS. Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011; 120: 91-7
|
|
|
|
|
|
11) Gutierrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the “trade-off"hypothesis. Clin J Am Soc Nephrol. 2010; 5: 1710-6
|
|
|
|
|
|
12) Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64: 2272-9
|
|
|
|
|
|
13) Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010; 21: 1427-35
|
|
|
|
|
|
14) Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79: 1370-8
|
|
|
|
|
|
15) Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-92
|
|
|
|
|
|
16) Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18: 2600-8
|
|
|
|
|
|
17) Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305: 2432-9
|
|
|
|
|
|
18) Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119: 2545-52
|
|
|
|
|
|
19) Mirza MA, Larsson A, Melhus H, et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009; 207: 546-51
|
|
|
|
|
|
20) Faul C, Amaral AP, Wolf M, et al. FGF 23 induces left ventricular hypertrophy. J Clin Invest. 2011 (in press)
|
|
|
|
|